COVIGEN / BioNet Asia, Technovalia - LARVOL DELTA

Dispersion patterns of SARS-CoV-2 variants Gamma, Lambda and Mu in Latin America and the Caribbean. (PubMed, Nat Commun) - "Through the COVID-19 Genomic Surveillance Regional Network (COVIGEN), LAC countries produced an important number of genomic sequencing data that made possible an enhanced SARS-CoV-2 genomic surveillance capacity in the Americas, paving the way for characterization of emerging variants and helping to guide the public health response...Our phylogenetic analysis revealed that the spread of variants Gamma, Lambda and Mu reflects human mobility patterns due to variations of international air passenger transportation and gradual lifting of social distance measures previously implemented in countries. Our results highlight the potential of genetic data to reconstruct viral spread and unveil preferential routes of viral migrations that are shaped by human mobility patterns."

Journal • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

COVALIA: The Safety and Immunogenicity of a DNA-based Vaccine (COVIGEN) in Healthy Volunteers (clinicaltrials.gov) - P1 | N=68 | Completed | Sponsor: University of Sydney | Active, not recruiting ➔ Completed

Trial completion • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases • IL2

COVALIA: The Safety and Immunogenicity of a DNA-based Vaccine (COVIGEN) in Healthy Volunteers (clinicaltrials.gov) - P1 | N=68 | Active, not recruiting | Sponsor: University of Sydney | Recruiting ➔ Active, not recruiting | N=200 ➔ 68

Enrollment change • Enrollment closed • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases • IL2

COVALIA: The Safety and Immunogenicity of a DNA-based Vaccine (COVIGEN) in Healthy Volunteers (clinicaltrials.gov) - P1 | N=200 | Recruiting | Sponsor: University of Sydney | N=150 ➔ 200 | Trial completion date: Dec 2022 ➔ Jun 2023 | Trial primary completion date: Feb 2022 ➔ Jun 2022

Enrollment change • Trial completion date • Trial primary completion date • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases • IFNG • IL2

COVALIA: The Safety and Immunogenicity of a DNA-based Vaccine (COVIGEN) in Healthy Volunteers (clinicaltrials.gov) - P1; N=150; Recruiting; Sponsor: University of Sydney; Not yet recruiting ➔ Recruiting; Initiation date: Feb 2021 ➔ Jun 2021; Trial primary completion date: Jun 2022 ➔ Feb 2022

Clinical • Enrollment open • Trial initiation date • Trial primary completion date • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases • IFNG • IL2

COVALIA: The Safety and Immunogenicity of a DNA-based Vaccine (COVIGEN) in Healthy Volunteers (clinicaltrials.gov) - P1; N=150; Not yet recruiting; Sponsor: University of Sydney

Clinical • New P1 trial • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases